An update from Springworks Therapeutics (SWTX) is now available.
SpringWorks Therapeutics has been notified that GlaxoSmithKline will terminate their 2022 collaboration agreement regarding joint clinical trials, effective six months after the notice. Despite this, the ongoing trials for a multiple myeloma treatment will continue until completion for the current patients. SpringWorks will still provide support and supply for these trials without incurring any financial penalties from the contract’s end, and retains the rights to further develop and market its products.
For a thorough assessment of SWTX stock, go to TipRanks’ Stock Analysis page.
